While the mechanism underlying KL‐VSHET action remains to be fully elucidated, the identification of new genetic variants that positively modify AD risk, such as KLOTHO, will bring to light novel molecular targets for future therapeutic trials. This evidence concerns the gene KL and Alzheimer disease.